Qualified Areas under the Public Works and Economic Development Act of 1965, as Amended, Public Law 89-136

Title Varies: Qualified Areas under the Public Works and Economic Development Act of 1965, Public Law 89-136; Areas Eligible for Financial Assistance Designated under the Public Works and Economic Development Act of 1965; Qualified Areas, Criteria and Data under the Public Works and Economic Development Act of 1965 Public Law 89-136

Saadia Al-fajjûmi's arabische Psalmenübersetzung und Commentar (Psalm 73-89) : nach einer Münchener, einer Berliner und einer Oxforder Handschrift herausgegeben, übersetzt und mit Anmerkungen versehen

von Dr. Siegfried Galliner

Global compilation of benthic data sets I

Approaches to quantify the organic carbon accumulation on a global scale generally do not consider the small-scale variability of sedimentary and oceanographic boundary conditions along continental margins. In this study, we present a new approach to regionalize the total organic carbon (TOC) content in surface sediments (<5 cm sediment depth). It is based on a compilation of more than 5500 single measurements from various sources. Global TOC distribution was determined by the application of a combined qualitative and quantitative-geostatistical method. Overall, 33 benthic TOC-based provinces were defined and used to process the global distribution pattern of the TOC content in surface sediments in a 1°x1° grid resolution. Regional dependencies of data points within each single province are expressed by modeled semi-variograms. Measured and estimated TOC values show good correlation, emphasizing the reasonable applicability of the method. The accumulation of organic carbon in marine surface sediments is a key parameter in the control of mineralization processes and the material exchange between the sediment and the ocean water. Our approach will help to improve global budgets of nutrient and carbon cycles.

Fragm. lat. VI 89 - Breviarium (Septem Machabei)

Trägerband: Ms. lat. oct. 15 Bd. 1; Vorbesitzer: Heinrich Kellner; Johann Maximilian Zum Jungen

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

OBJECTIVE: To evaluate the cost-effectiveness of adding zoledronic acid or strontium-89 to standard docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC).

PATIENTS AND METHODS: Data on resource use and quality of life for 707 patients collected prospectively in the TRAPEZE 2 × 2 factorial randomised trial (ISRCTN 12808747) were used to assess the cost-effectiveness of i) zoledronic acid versus no zoledronic acid (ZA vs. no ZA), and ii) strontium-89 versus no strontium-89 (Sr89 vs. no Sr89). Costs were estimated from the perspective of the National Health Service in the UK and included expenditures for trial treatments, concomitant medications, and use of related hospital and primary care services. Quality-adjusted life-years (QALYs) were calculated according to patients' responses to the generic EuroQol EQ-5D-3L instrument, which evaluates health status. Results are expressed as incremental cost-effectiveness ratios (ICERs) and cost-effectiveness acceptability curves.

RESULTS: The per-patient cost for ZA was £12 667, £251 higher than the equivalent cost in the no ZA group. Patients in the ZA group had on average 0.03 QALYs more than their counterparts in no ZA group. The ICER for this comparison was £8 005. Sr89 was associated with a cost of £13 230, £1365 higher than no Sr89, and a gain of 0.08 QALYs compared to no Sr89. The ICER for Sr89 was £16 884. The probabilities of ZA and Sr89 being cost-effective were 0.64 and 0.60, respectively.

CONCLUSIONS: The addition of bone-targeting treatments to standard chemotherapy led to a small improvement in QALYs for a modest increase in cost (or cost-savings). ZA and Sr89 resulted in ICERs below conventional willingness-to-pay per QALY thresholds, suggesting that their addition to chemotherapy may represent a cost-effective use of resources.

Evaluación de la posición del huevo incubable (día 3, 5 y 7) de los lotes de reproductoras pesadas (88-89-90-91 y 92) de la línea Ross 308

Tesis (Zootecnista). -- Universidad de La Salle. Facultad de Ciencias Agropecuarias. Programa de Zootecnia, 2015

Annual Report Fiscal Year 1988-89

The South Carolina State Ports Authority published an annual report with information about the board and senior management, independent auditor report, and financial statements. This annual report ceased after 2005, although they still publish annual financial statements.

Paradojas alrededor del 89

IntroducciónEs muy propicia la fecha para reflexionar sobre los orígenes y trayectoria de nuestra democracia, aunque pienso que se ha exagerado por parte de quienes desean verla como un fenómeno (hecho o estructura?) originado en 7 de noviembre de 1889 y que este año cumple cien años (de que?)…

El 89 de Costa Rica: otra interpretación del levantamiento del 7 de Noviembre

Introducción El azar es, sin duda, irónico, tras 100 años, 3 meses y 4 días del”89” francés, San José el suyo, pero sin Bastilla y casi falto de sangre. La “oficialización” de 1989 como año del “centenario de la democracia costarricense”, que suscita desde 1988 los mas diversos pareceres, es después de todo y no únicamente desde la perspectiva del bufón y el cortesano. La designación, aparte del circo y la maroma que supone de por si, invita a evaluar con cierto detalle: a la trayectoria de la historiografía política nacional; b el contexto social de la movilización plebeya; y c el problema histórico de la democracia en  Costa Rica

Prognostic Value Of Dna And Mrna E6/e7 Of Human Papillomavirus In The Evolution Of Cervical Intraepithelial Neoplasia Grade 2.

This study aimed at evaluating whether human papillomavirus (HPV) groups and E6/E7 mRNA of HPV 16, 18, 31, 33, and 45 are prognostic of cervical intraepithelial neoplasia (CIN) 2 outcome in women with a cervical smear showing a low-grade squamous intraepithelial lesion (LSIL). This cohort study included women with biopsy-confirmed CIN 2 who were followed up for 12 months, with cervical smear and colposcopy performed every three months. Women with a negative or low-risk HPV status showed 100% CIN 2 regression. The CIN 2 regression rates at the 12-month follow-up were 69.4% for women with alpha-9 HPV versus 91.7% for other HPV species or HPV-negative status (P < 0.05). For women with HPV 16, the CIN 2 regression rate at the 12-month follow-up was 61.4% versus 89.5% for other HPV types or HPV-negative status (P < 0.05). The CIN 2 regression rate was 68.3% for women who tested positive for HPV E6/E7 mRNA versus 82.0% for the negative results, but this difference was not statistically significant. The expectant management for women with biopsy-confirmed CIN 2 and previous cytological tests showing LSIL exhibited a very high rate of spontaneous regression. HPV 16 is associated with a higher CIN 2 progression rate than other HPV infections. HPV E6/E7 mRNA is not a prognostic marker of the CIN 2 clinical outcome, although this analysis cannot be considered conclusive. Given the small sample size, this study could be considered a pilot for future larger studies on the role of predictive markers of CIN 2 evolution.